caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1821189580

Kimberly KoenigM.D.

PRACTICEMDACCSee all providers at this practice →
Hematology-OncologyHouston, TXI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Kimberly Koenig's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 9 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER1871,433
Hubert Chuang
Nuclear Medicine · Houston, TX
2243
Beth Chasen
Nuclear Medicine · Houston, TX
1945
Mark Dryden
Diagnostic Radiology · Houston, TX
1522
Beatriz Adrada
Diagnostic Radiology · Houston, TX
1434
Quest Diagnostics Clinical Laboratories Inc
Clinical Laboratory · Houston, TX
1270
FORNAGE, BRUNO1116
Beverly Rhodes
Nurse Practitioner · Houston, TX
1114
Kara Thompson
Cardiology · Houston, TX
1124
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
175
Unique beneficiaries
—
Total services
293
Distinct HCPCS
3
Medicare payment
$24K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 613 Hematology-Oncology providers in TX — bottom quintile (cohort median 2,625).
PRESCRIBING · PART D · 2024
Total Rx claims
359
Beneficiaries
—
Total drug cost
$768K
Distinct drugs
16
Brand share
24.2%
Top prescribed drugs
Anastrozole72 claims
Tamoxifen Citrate52 claims
Abemaciclib29 claims
Letrozole25 claims
Exemestane25 claims
QUALITY · MIPS · 2024
Final MIPS score
84.3
Quality
70.8
Cost
67.6
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.39%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.